全文获取类型
收费全文 | 8400篇 |
免费 | 741篇 |
国内免费 | 161篇 |
专业分类
耳鼻咽喉 | 55篇 |
儿科学 | 180篇 |
妇产科学 | 135篇 |
基础医学 | 524篇 |
口腔科学 | 116篇 |
临床医学 | 1239篇 |
内科学 | 977篇 |
皮肤病学 | 48篇 |
神经病学 | 369篇 |
特种医学 | 162篇 |
外科学 | 744篇 |
综合类 | 1040篇 |
预防医学 | 1478篇 |
眼科学 | 51篇 |
药学 | 760篇 |
19篇 | |
中国医学 | 118篇 |
肿瘤学 | 1287篇 |
出版年
2024年 | 25篇 |
2023年 | 241篇 |
2022年 | 356篇 |
2021年 | 535篇 |
2020年 | 504篇 |
2019年 | 500篇 |
2018年 | 451篇 |
2017年 | 415篇 |
2016年 | 385篇 |
2015年 | 378篇 |
2014年 | 736篇 |
2013年 | 766篇 |
2012年 | 518篇 |
2011年 | 559篇 |
2010年 | 345篇 |
2009年 | 376篇 |
2008年 | 361篇 |
2007年 | 300篇 |
2006年 | 256篇 |
2005年 | 195篇 |
2004年 | 168篇 |
2003年 | 88篇 |
2002年 | 86篇 |
2001年 | 68篇 |
2000年 | 61篇 |
1999年 | 54篇 |
1998年 | 51篇 |
1997年 | 42篇 |
1996年 | 49篇 |
1995年 | 52篇 |
1994年 | 40篇 |
1993年 | 40篇 |
1992年 | 25篇 |
1991年 | 31篇 |
1990年 | 29篇 |
1989年 | 25篇 |
1988年 | 28篇 |
1987年 | 25篇 |
1986年 | 17篇 |
1985年 | 22篇 |
1984年 | 17篇 |
1983年 | 8篇 |
1982年 | 7篇 |
1981年 | 10篇 |
1980年 | 13篇 |
1979年 | 11篇 |
1978年 | 5篇 |
1977年 | 6篇 |
1976年 | 10篇 |
1975年 | 6篇 |
排序方式: 共有9302条查询结果,搜索用时 203 毫秒
11.
背景 全科医生数量和质量是人力资源管理的两个重要维度,其中,医生数量的新增、保持和流失,是全科人力动态规划、管理和评价的重要考量,也是全科住院医师规范化培训(简称全科住培)的绩效指标。探讨全科住培学员的就业状况及影响因素,可以为今后住培政策和激励机制的制定提供参考,但目前针对非订单定向全科住培学员的相关研究较为缺乏。 目的 了解河南省非订单定向全科住培学员的就业状况,分析学员结业后未从事全科医学相关工作的原因,从而为完善培训管理和人力资源激励机制提供参考。 方法 于2021年8月,采用分层随机整群抽样法,在河南省选取2014—2017年入培且已结业的非订单定向全科住培学员326例进行问卷调查。问卷由课题组自行设计,主要内容为学员的基本信息、全科住培情况、目前工作情况及结业后从事与未从事全科医学相关工作的原因。问卷通过"问卷星"平台发放,由学员自行填写。 结果 共发放问卷326份,回收有效问卷271份(83.1%)。结业后,从事全科医学相关工作者77例(28.4%),从事非全科医学相关工作者194例(71.6%)。多因素Logistic回归分析结果显示,年龄、文化程度、生源类型、全科住培基地所在区域是学员结业后是否从事全科医学相关工作的影响因素(P<0.05)。与结业后未从事全科医学相关工作的学员相比,结业后从事全科医学相关工作学员注册为全科医学专业的比例更高〔70.1%(54/77)比32.0%(62/194),P<0.05〕,在乡镇卫生院/社区卫生服务中心执业的比例更高〔49.4%(38/77)比6.2%(12/194),P<0.05)〕。194例未从事全科医学相关工作的学员中,从事内科学工作者78例(40.2%),从事急诊及危重症医学工作者33例(17.0%),从事外科学工作者17例(8.8%)。不选择从事全科医学相关工作的前3位原因分别为:单位安排〔34.5%(67/194)〕,所在单位没有全科医学科〔29.9%(58/194)〕,薪酬低〔26.8%(52/194)〕。 结论 非订单定向全科住培学员选择从事全科医学相关工作的比例较低,年龄、文化程度、生源类型及基地所在区域是影响因素。建议加大全科医学理念宣传,加快综合医院全科医学科建设,提高全科医生薪酬待遇,以此增加全科医生的职业吸引力。 相似文献
12.
13.
目的 探讨微信小程序合并时间管理器在眼科患儿出院宣教中的应用效果,为眼科护士出院宣教干预提供借鉴。方法 采用便利抽样法,选取98例眼科患儿监护人作为研究对象,将2021年2月-5月住院的49例患儿的监护人作为对照组,进行眼科常规出院宣教,将2021年6月-9月住院的49例患儿的监护人作为观察组,使用微信小程序合并时间管理器进行出院宣教干预。比较2组患儿监护人对疾病相关知识知晓情况、满意度及按时复诊人数。结果 干预1个月后,观察组疾病相关知识问卷得分、满意度得分及按时复诊率均高于对照组(t=-5.223,P=0.001;t=-5.419,P=0.001;χ2=6.874,P=0.009)。结论 使用微信小程序合并时间管理器在眼科病房进行出院宣教,能有效提高患儿监护人出院后疾病相关知识水平、按时就诊率及监护人满意度,提升护理服务质量。 相似文献
14.
15.
《Clinical colorectal cancer》2020,19(4):285-290
BackgroundFOLFIRI (irinotecan, 5-fluorouracil, and leucovorin) + aflibercept improves median overall survival (OS) and progression-free survival (PFS) in patients with previously treated metastatic colorectal cancer (mCRC). Our aim was to investigate efficacy and tolerability of this combination in the first line.Patients and MethodsPatients with untreated documented mCRC received aflibercept plus FOLFIRI every 14 days until progression or unacceptable toxicity in an open, phase II single-arm, multicenter trial. The primary endpoint was the 6-month PFS rate. Secondary endpoints were OS and tolerability. A 2-step Simon design was used with H0: 55% and H1= 75%. Data were analyzed in intention to treat.ResultsForty-one patients were included, and 40 were analyzed (1 consent withdrawal) in 9 French centers between October 2014 and February 2017. The median age was 65 years (range, 46-81 years), 55% had ≥ 2 metastatic sites, and 50% and 15% had RAS and BRAF mutations, respectively. Twenty-two (54.5%; 95% confidence interval, 38.9%-68.5%) patients were alive and non-progressive at 6 months. FOLFIRI + aflibercept was considered ineffective, resulting in the cessation of inclusions. The median follow-up was 34 months. The overall response rate was 55%, and the disease control rate was 80%. The median duration of treatment was 5.3 months; the median PFS and OS were 8.2 and 18.6 months, respectively. Grade 3 to 4 adverse events were mainly gastrointestinal (47.5%) and vascular (32.5%). Of the patients, 87.5% had at least 1 dose modification.ConclusionAlthough the primary objective was not met, first-line FOLFIRI + aflibercept for mCRC leads to median PFS and OS close to those reported with classical doublet and targeted agents, but with significant toxicities needing dose reduction. 相似文献
16.
Narges K Tafreshi David L Morse Marie Catherine Lee 《World journal of clinical oncology》2020,11(4):169-179
Triple-negative breast cancer (TNBC) is defined as a type of breast cancer with lack of expression of estrogen receptor, progesterone receptor and human epidermal growth factor 2 protein. In comparison to other types of breast cancer, TNBC characterizes for its aggressive behavior, more prone to early recurrence and a disease with poor response to molecular target therapy. Although TNBC is identified in only 25%-30% of American breast cancer cases annually, these tumors continue to be a therapeutic challenge for clinicians for several reasons: Tumor heterogeneity, limited and toxic systemic therapy options, and often resistance to current standard therapy, characterized by progressive disease on treatment, residual tumor after cytotoxic chemotherapy, and early recurrence after complete surgical excision. Cell-surface targeted therapies have been successful for breast cancer in general, however there are currently no approved cell-surface targeted therapies specifically indicated for TNBC. Recently, several cell-surface targets have been identified as candidates for treatment of TNBC and associated targeted therapies are in development. The purpose of this work is to review the current clinical challenges posed by TNBC, the therapeutic approaches currently in use, and provide an overview of developing cell surface targeting approaches to improve outcomes for treatment resistant TNBC. 相似文献
17.
18.
目的 探讨员工援助计划服务对心内科护士职业认同感、职业价值观、职业压力的影响。 方法 选择2018年1-3月我院心内科护理人员58名,为其实施员工援助计划服务,评价实施前后心内科护士的职业认同感、职业价值观、职业压力感知、职业压力反应。 结果 实施后,心内科护士工作压力源各维度评分、压力感知与压力反应各维度得分均较实施前下降(P<0.05);职业价值观各维度及职业认同感各维度评分均较实施前显著提高(P<0.001)。 结论 员工援助计划可提高心内科护士职业认同感、职业价值观,缓解其职业压力感知以及职业压力反应。 相似文献
19.
《Clinical breast cancer》2020,20(1):80-86
BackgroundEpidermal growth factor receptor (EGFR) is frequently overexpressed in metastatic triple-negative breast cancer (mTNBC). One strategy for overcoming resistance to EGFR inhibition is concomitant inhibition of downstream signaling. The antidiabetic drug metformin inhibits both MAPK and PI3K/mTOR pathway signaling. We evaluated the combination of erlotinib and metformin in a phase 1 study of patients with mTNBC.Patients and MethodsPatients with mTNBC who had received at least one prior line of therapy for metastatic disease were eligible. Erlotinib dose was fixed at 150 mg daily. Metformin dose escalation was planned according to a 3 + 3 design. Dose-limiting toxicities (DLT) were assessed during the first 5 weeks of therapy. The primary objective was to determine the maximum tolerated dose of metformin with fixed-dose erlotinib. Secondary endpoints were response rate, stable disease rate, and progression-free survival.ResultsEight patients were enrolled. The median number of prior therapies for metastatic disease was 2.5 (range, 1-6). No DLT events were reported during the DLT assessment period. Most adverse events were grade 1/2. Grade 3 diarrhea despite maximum supportive care required dose reduction of metformin in one patient. Grade 3 rash led to study withdrawal in one patient. No grade 4 adverse events were reported. The best observed response was stable disease in 2 patients (25%). Median progression-free survival was 60 days (range, 36-61 days).ConclusionErlotinib and metformin were well tolerated in a population of pretreated mTNBC patients but did not demonstrate efficacy in this population. 相似文献
20.
目的 探讨NRP-1单克隆抗体(NRP-1 MAb)的特异性,以及不同剂量的NRP-1 MAb治疗乳腺癌裸鼠移植瘤的疗效。方法 Western blot和共聚焦免疫荧光法检测NRP-1 MAb是否识别MCF7细胞上NRP-1蛋白。将MCF7细胞接种于BALB/c裸鼠皮下建立乳腺癌细胞移植瘤模型,并进行瘤组织传代。传代的肿瘤体积生长至300~500 mm3时,随机分为对照组、NRP-1 MAb低剂量组、中剂量组和高剂量组,每组6只,给药7次。观察荷瘤裸鼠一般状况,测量瘤体大小及裸鼠体重。实验结束时剥离瘤体称重,提取组织蛋白,Western blot检测组织中VEGF蛋白和NRP-1蛋白的表达量。结果 NRP-1MAb成功识别MCF7细胞上的NRP-1蛋白;NRP-1 MAb能够有效抑制MCF7细胞裸鼠移植瘤的生长,低剂量组(1 mg/kg)抑瘤率为47.01%,中剂量组(5 mg/kg)抑瘤率为65.70%,高剂量组(10 mg/kg)抑瘤率为69.19%。。结论 NRP-1 MAb能够识别并有效结合MCF7细胞膜上的NRP-1蛋白,且可抑制MCF7细胞移植瘤的生长,NRP-1 MAb抑制移植瘤的增长可能与下调NRP-1和VEGF表达有关。 相似文献